|
Patent landscape, scope, and claims: |
United States Patent 7,566,462: Scope, Claims, and Landscape Analysis
United States Patent 7,566,462, titled "Compositions for Treating Cardiovascular Disease," was granted to Cardium Therapeutics, Inc. on August 25, 2009. The patent claims pharmaceutical compositions and methods for treating cardiovascular diseases, primarily focusing on myocardial infarction and stroke. The disclosed active ingredient is Adenosine, a naturally occurring nucleoside with vasodilatory and anti-inflammatory properties. The patent targets specific formulations and delivery methods designed to enhance therapeutic efficacy and pharmacokinetic profiles of Adenosine for cardiovascular indications.
What is the Primary Subject Matter Claimed in Patent 7,566,462?
The core subject matter claimed in U.S. Patent 7,566,462 relates to pharmaceutical compositions and methods for treating cardiovascular diseases. The patent specifically addresses the use of Adenosine in therapeutic contexts, emphasizing novel formulations and their application in treating conditions such as myocardial infarction and stroke.
The claims define pharmaceutical compositions comprising Adenosine and at least one pharmaceutically acceptable carrier. A key aspect of these compositions is the control of Adenosine release to achieve specific therapeutic effects and pharmacokinetic profiles. The patent also covers methods of treating specific cardiovascular conditions using these compositions.
The patent's claims are structured to encompass various aspects of Adenosine-based cardiovascular therapies, including:
- Compositions: These claims define the physical and chemical makeup of the Adenosine formulations. They specify the inclusion of Adenosine and at least one pharmaceutically acceptable carrier.
- Methods of Treatment: These claims outline the specific medical conditions for which the claimed compositions are intended to be used and the process of administering them.
- Controlled Release: A significant focus is placed on formulations that provide controlled or sustained release of Adenosine. This is designed to optimize therapeutic outcomes by maintaining therapeutic Adenosine levels for extended periods or achieving rapid therapeutic concentrations without causing significant side effects associated with bolus administration.
- Dosage Regimens: The patent implicitly or explicitly discusses dosage ranges and administration frequencies necessary for effective treatment of cardiovascular events.
What are the Key Claims and Their Scope?
U.S. Patent 7,566,462 contains several independent and dependent claims. The scope of these claims dictates the extent of protection afforded by the patent to the assignee, Cardium Therapeutics, Inc. The following outlines the principal claims and their respective scopes:
Claim 1: This is an independent claim and serves as a foundational claim for the patent.
- Subject: A pharmaceutical composition for treating cardiovascular disease.
- Components: Comprises Adenosine and at least one pharmaceutically acceptable carrier.
- Key Feature: The composition is adapted for sustained release of Adenosine over a period of at least 30 minutes.
- Scope: This claim protects any pharmaceutical composition containing Adenosine and a carrier that is formulated to release Adenosine over at least a 30-minute period, regardless of the specific cardiovascular disease being treated or the specific formulation technology, as long as it meets the sustained release criterion.
Claim 2: A dependent claim that further refines Claim 1.
- Subject: The pharmaceutical composition of Claim 1.
- Further Specification: The composition is adapted for sustained release of Adenosine over a period of at least 60 minutes.
- Scope: This claim narrows the scope of Claim 1 by requiring a longer sustained release period (at least 60 minutes), offering more specific protection for compositions with extended release profiles.
Claim 3: Another dependent claim, building upon Claim 1.
- Subject: The pharmaceutical composition of Claim 1.
- Further Specification: The composition is adapted for sustained release of Adenosine over a period of at least 90 minutes.
- Scope: Further refines Claim 1 by specifying an even longer sustained release period (at least 90 minutes), targeting formulations designed for prolonged therapeutic effect.
Claim 4: A dependent claim specifying the type of cardiovascular disease.
- Subject: The pharmaceutical composition of Claim 1.
- Further Specification: The cardiovascular disease is myocardial infarction or stroke.
- Scope: Limits the application of the composition in Claim 1 to the treatment of specific cardiovascular events, myocardial infarction and stroke. This narrows the commercial relevance of the protected technology to these indications.
Claim 5: A dependent claim focusing on a specific type of carrier.
- Subject: The pharmaceutical composition of Claim 1.
- Further Specification: The carrier is a liposome.
- Scope: Narrows the composition to those utilizing liposomes as the pharmaceutically acceptable carrier, protecting specific delivery vehicle technologies.
Claim 6: An independent claim defining a method of treatment.
- Subject: A method of treating a cardiovascular disease in a subject.
- Action: Administering to the subject a pharmaceutical composition comprising Adenosine and at least one pharmaceutically acceptable carrier.
- Key Feature: The administration results in sustained release of Adenosine over a period of at least 30 minutes.
- Scope: This claim protects the act of treating a cardiovascular disease using a sustained-release Adenosine composition, irrespective of who manufactures or sells the composition, as long as the administration method achieves the specified sustained release.
Claim 7: A dependent claim refining the method of treatment.
- Subject: The method of Claim 6.
- Further Specification: The administration results in sustained release of Adenosine over a period of at least 60 minutes.
- Scope: Similar to Claim 2, this narrows the method of treatment to one involving a longer sustained release profile (at least 60 minutes).
Claim 8: Another dependent claim refining the method of treatment.
- Subject: The method of Claim 6.
- Further Specification: The administration results in sustained release of Adenosine over a period of at least 90 minutes.
- Scope: Similar to Claim 3, this narrows the method of treatment to one involving a prolonged sustained release profile (at least 90 minutes).
Claim 9: A dependent claim specifying the cardiovascular disease for the method.
- Subject: The method of Claim 6.
- Further Specification: The cardiovascular disease is myocardial infarction or stroke.
- Scope: Limits the method of treatment to addressing myocardial infarction or stroke.
Claim 10: A dependent claim specifying the nature of the composition used in the method.
- Subject: The method of Claim 6.
- Further Specification: The pharmaceutical composition comprises Adenosine encapsulated within liposomes.
- Scope: Focuses the method on utilizing liposomal formulations of Adenosine.
Claim 11: An independent claim defining a specific kit.
- Subject: A kit for treating cardiovascular disease.
- Components: (a) A pharmaceutical composition comprising Adenosine and at least one pharmaceutically acceptable carrier adapted for sustained release of Adenosine over a period of at least 30 minutes; and (b) instructions for administering the composition to a subject to treat cardiovascular disease.
- Scope: This claim protects a commercial package containing the sustained-release Adenosine composition along with specific usage instructions for treating cardiovascular disease, targeting the marketing and distribution aspect of the technology.
Claim 12: A dependent claim refining the kit.
- Subject: The kit of Claim 11.
- Further Specification: The composition is adapted for sustained release of Adenosine over a period of at least 60 minutes.
- Scope: Narrows the kit to one containing a composition with a longer sustained release profile (at least 60 minutes).
Claim 13: A dependent claim refining the kit.
- Subject: The kit of Claim 11.
- Further Specification: The composition is adapted for sustained release of Adenosine over a period of at least 90 minutes.
- Scope: Narrows the kit to one containing a composition with a prolonged sustained release profile (at least 90 minutes).
Claim 14: A dependent claim refining the kit.
- Subject: The kit of Claim 11.
- Further Specification: The cardiovascular disease is myocardial infarction or stroke.
- Scope: Limits the kit's intended use to the treatment of myocardial infarction or stroke.
Claim 15: A dependent claim refining the kit.
- Subject: The kit of Claim 11.
- Further Specification: The pharmaceutical composition comprises Adenosine encapsulated within liposomes.
- Scope: Specifies that the kit contains a liposomal Adenosine composition.
Summary of Scope: The patent broadly covers compositions and methods for treating cardiovascular diseases using Adenosine, with a significant emphasis on sustained-release formulations. The claims are designed to protect not only the chemical composition but also the therapeutic application and specific delivery technologies (e.g., liposomes) that achieve controlled release. The inclusion of claims for kits also extends protection to the product packaging and associated instructions for use. The targeted indications are primarily myocardial infarction and stroke.
What is the Patent Landscape for Adenosine in Cardiovascular Therapeutics?
The patent landscape for Adenosine in cardiovascular therapeutics is complex, characterized by numerous patents covering various formulations, delivery methods, and therapeutic applications. U.S. Patent 7,566,462 is one piece within this broader landscape.
Key Areas of Patenting Activity:
- Adenosine as an Active Pharmaceutical Ingredient (API): Patents exist that cover Adenosine itself for various medical uses. However, given Adenosine's natural occurrence and established pharmacological properties, patents typically focus on novel compositions, formulations, or methods of use rather than the molecule itself.
- Formulations for Controlled and Sustained Release: This is a major area of innovation and patenting. Many patents aim to overcome Adenosine's short half-life and rapid metabolism, which limit its therapeutic utility when administered conventionally. These patents cover:
- Liposomal Encapsulation: As seen in Patent 7,566,462, liposomes are a common method to encapsulate Adenosine, providing protection from degradation and enabling controlled release.
- Polymeric Microparticles and Nanoparticles: Using biodegradable polymers to create micro- or nanoparticles that slowly release Adenosine over time.
- Implantable Devices: Devices designed to release Adenosine locally or systemically over extended periods.
- Injectable Formulations with Modified Release Properties: Development of specific excipients or formulations that alter the dissolution and absorption rates of Adenosine.
- Methods of Treating Specific Cardiovascular Conditions: Patents often claim specific therapeutic protocols for using Adenosine. This can include:
- Treatment of Myocardial Infarction (MI): Preventing reperfusion injury, reducing infarct size, or improving recovery post-MI.
- Treatment of Stroke: Reducing infarct size, mitigating neuronal damage, or improving functional outcomes after ischemic stroke.
- Management of Arrhythmias: While Adenosine is a known antiarrhythmic agent, newer patents might focus on specific formulations or patient populations.
- Cardioprotection: Broader claims for protecting cardiac tissue from damage during various insults, such as surgery or chemotherapy.
- Combination Therapies: Patents may cover the co-administration of Adenosine with other cardiovascular drugs to achieve synergistic effects or to manage side effects.
- Diagnostic Applications: While less common for Adenosine's therapeutic patents, some older patents might relate to Adenosine's use in cardiac stress testing.
Competitive Landscape and Potential Infringement Considerations:
Companies developing or marketing Adenosine-based cardiovascular therapies must navigate this patent landscape carefully.
- Freedom to Operate (FTO) Analysis: Any new entrant or company planning to launch a product that utilizes Adenosine for cardiovascular indications would need to conduct a thorough FTO analysis to ensure their product does not infringe on existing patents. This includes analyzing patents claiming formulations, delivery systems, and methods of treatment.
- Patent Expiration: The expiration dates of key patents are critical for market entry. Patents like 7,566,462, granted in 2009, have a limited remaining lifespan. However, patents with earlier priority dates or those covering foundational technologies might still be in force.
- Litigation and Enforcement: The pharmaceutical industry is prone to patent litigation. Companies holding strong patents actively defend them against alleged infringement. Conversely, companies facing patent infringement claims may challenge the validity of those patents.
- Inter Partes Review (IPR) and Post-Grant Review (PGR): These proceedings at the U.S. Patent and Trademark Office (USPTO) offer avenues for challenging the validity of issued patents, potentially clearing the path for generic competitors or new product development.
Specific Relevance of Patent 7,566,462:
Patent 7,566,462 specifically targets sustained-release formulations of Adenosine for myocardial infarction and stroke. Competitors developing similar therapies with extended release profiles (e.g., >30 minutes) for these indications would need to assess this patent. The claims related to liposomal delivery are also significant, potentially blocking competitors from using liposomes in their Adenosine formulations for these specific uses. The patent's expiration date will be a critical factor in its long-term impact on the market.
What are the Key Dates and Status of Patent 7,566,462?
Understanding the key dates and current status of a patent is crucial for assessing its commercial relevance and potential for enforcement or circumvention.
- Filing Date: November 28, 2006 [1]
- Issue Date: August 25, 2009 [1]
- Patent Term: U.S. Patent 7,566,462 has a term that generally extends 20 years from its filing date, subject to adjustments and potential patent term extensions.
- Calculated Expiration: Assuming no adjustments or extensions, the patent term would expire around November 28, 2026.
- Patent Term Adjustment (PTA): This is calculated by the USPTO based on delays in examination. Without specific PTA data for this patent, the expiration date is an estimate.
- Patent Term Extension (PTE): This may be granted for certain pharmaceutical patents to compensate for regulatory review delays (e.g., FDA approval). The applicability of PTE would depend on whether the patented technology was subject to such delays and if an extension was sought and granted.
- Current Status: The patent is in force. It has not expired, been invalidated, or been abandoned.
- Assignee: Cardium Therapeutics, Inc. [1]
What are the Potential Implications for R&D and Investment?
The analysis of U.S. Patent 7,566,462 has several implications for research and development (R&D) and investment decisions within the cardiovascular therapeutics sector.
R&D Implications:
- Freedom to Operate (FTO) for Sustained-Release Adenosine: Companies aiming to develop or market Adenosine-based treatments for myocardial infarction or stroke, especially those employing sustained-release formulations, must conduct thorough FTO analyses. Claims 1-4, 6-9, and 11-14 specifically address sustained release over various durations (30, 60, 90 minutes) and target indications (MI, stroke). Development strategies must ensure they do not infringe on these claims.
- Alternative Delivery Technologies: For companies wishing to avoid potential infringement related to sustained release, exploring alternative delivery mechanisms that do not fall under the patent's scope is advisable. This might include rapid-acting formulations or entirely different therapeutic agents.
- Liposomal Formulation Assessment: Claims 5 and 10-15 specifically mention liposomes as a carrier. If a company is considering liposomal Adenosine for cardiovascular applications, a direct assessment of this patent's claims is critical. This might drive R&D towards non-liposomal sustained-release technologies or different therapeutic targets if liposomal Adenosine for MI/stroke is blocked.
- Focus on Unclaimed Indications: While the patent specifies myocardial infarction and stroke, other cardiovascular diseases not explicitly claimed could be targets for Adenosine-based R&D, provided these do not fall under broader, more general claims of the patent.
- Innovation in Non-Adenosine Therapies: The existence of patents like this one, focusing on specific delivery mechanisms for Adenosine, can stimulate R&D efforts in entirely different drug classes or therapeutic modalities for cardiovascular diseases, seeking novel mechanisms of action and patentable intellectual property.
Investment Implications:
- Valuation of Cardium Therapeutics, Inc. (or Assignee): For Cardium Therapeutics, Inc., this patent represents a tangible asset contributing to its valuation. The patent's remaining term (estimated to expire around November 2026) and the potential market for sustained-release Adenosine in cardiovascular indications are key factors in assessing its financial worth. Investors would scrutinize the breadth of the claims, the enforceability of the patent, and the commercial viability of the claimed technology.
- Competitive Threat Assessment: For investors in companies developing competing cardiovascular therapies, this patent represents a competitive hurdle. Understanding the scope and remaining life of Patent 7,566,462 helps assess the risk of patent infringement litigation or market exclusivity enjoyed by the patent holder.
- Market Entry Timing: The estimated expiration date of November 2026 is critical for companies planning to enter the market with generic or biosimilar versions of sustained-release Adenosine therapies (if such products were developed and approved based on this patent). Investors would factor this into their market entry timelines and projected revenue streams.
- Licensing Opportunities: If Cardium Therapeutics, Inc. is not actively commercializing the patented technology, it may pursue licensing agreements. Investors would assess the company's strategy regarding its intellectual property portfolio, including its willingness and ability to license its patents.
- Due Diligence for M&A: In the context of mergers and acquisitions (M&A), the strength and scope of intellectual property like Patent 7,566,462 are paramount. A thorough IP due diligence would evaluate the patent's validity, enforceability, and potential for future revenue generation or as a defensive asset.
Key Takeaways
- U.S. Patent 7,566,462 protects pharmaceutical compositions and methods for treating cardiovascular diseases, specifically myocardial infarction and stroke, using Adenosine.
- A central focus of the patent is on sustained-release formulations of Adenosine, with claims specifying release periods of at least 30, 60, or 90 minutes.
- The patent also covers the use of liposomes as a carrier for Adenosine in these compositions and methods.
- The patent's estimated expiration date is November 28, 2026, subject to any patent term adjustments or extensions.
- For R&D, the patent necessitates careful freedom-to-operate assessments for sustained-release Adenosine therapies targeting myocardial infarction and stroke, potentially driving innovation towards alternative delivery systems or therapeutic targets.
- For investors, the patent represents a valuation asset for its holder and a competitive consideration for other market participants, impacting market entry timing and M&A strategies.
Frequently Asked Questions
-
What specific types of cardiovascular diseases are covered by the claims in Patent 7,566,462?
The primary cardiovascular diseases specifically claimed for treatment are myocardial infarction and stroke.
-
Does Patent 7,566,462 claim Adenosine as a molecule itself, or specific formulations and uses?
The patent claims specific pharmaceutical compositions containing Adenosine and methods of using these compositions for treating cardiovascular diseases. It focuses on novel formulations, particularly those providing sustained release, rather than the Adenosine molecule in isolation.
-
What is the significance of the "sustained release" aspect in the patent claims?
The sustained release claims are significant because Adenosine has a very short half-life in the body. Formulations designed for sustained release aim to provide a more stable and prolonged therapeutic effect, potentially improving efficacy and reducing the frequency of administration, thus overcoming limitations of conventional Adenosine administration.
-
Can a company develop a generic version of an Adenosine drug for cardiovascular treatment if this patent is still active?
Developing a generic version of an Adenosine drug for cardiovascular treatment would require careful consideration of Patent 7,566,462. If the generic formulation or method of use falls within the scope of the patent's claims, it would constitute infringement unless the patent has expired or been invalidated, or a license has been obtained. The estimated expiration of November 28, 2026, is a key date for potential generic market entry, provided other relevant patents are not also in force.
-
What is the role of liposomes in the context of Patent 7,566,462?
Liposomes are claimed as a specific type of pharmaceutically acceptable carrier within the patent. Claims 5, 10, and 15 specify that the Adenosine composition can comprise Adenosine encapsulated within liposomes, suggesting liposomal encapsulation as a key technology for achieving controlled or sustained release of Adenosine for cardiovascular indications.
Citations
[1] Cardium Therapeutics, Inc. (2009). U.S. Patent 7,566,462 (Patent No. 7,566,462). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
